TABLE 3

Comparison of IC50s between FL and GC samples in broth dilution assaysa

AntibioticbUnit (/ml)IC50
AμAUC
FLGCP valueFLGCP valueFLGCP value
6-MPμg82.7 ± 32.197.1 ± 13.20.51398 ± 8100 ± 110.77897 ± 5.997 ± 12.10.981
CIPng35.2 ± 3.140.6 ± 2.90.09119.6 ± 2.916.5 ± 3.90.33524.5 ± 3.726.6 ± 1.00.422
ENXμg1.59 ± 0.221.52 ± 0.350.7830.84 ± 0.051.07 ± 0.10.0561.45 ± 0.041.54 ± 0.070.106
LVXng44.6 ± 3.036.5 ± 7.50.15530.4 ± 5.941.6 ± 14.20.30523.3 ± 1339.2 ± 120.197
LMXng208 ± 36232 ± 520.540193 ± 8.2187 ± 530.862240 ± 40234 ± 380.863
NALμg3.41 ± 0.463.23 ± 0.130.7611.5 ± 0.041.8 ± 0.70.4813.04 ± 0.883.02 ± 0.720.976
NVBng494 ± 45462 ± 240.332407 ± 28407 ± 420.975455 ± 61440 ± 680.790
OXOng137 ± 14125 ± 4.70.269125 ± 4588 ± 2.30.289114 ± 11107 ± 210.658
OFLng101 ± 5.194 ± 5.70.16986 ± 5.788 ± 220.875105 ± 5106 ± 30.804
TPZμg27.2 ± 6.426.3 ± 3.20.84119.6 ± 1.920.5 ± 0.20.53820.3 ± 0.119.6 ± 0.50.132
  • a Data are presented as averages ± standard deviations (n = 3). P values were calculated using Student's t tests.

  • b Abbreviations: 6-MP, 6-mercaptopurine; CIP, ciprofloxacin; ENX, enoxacin; LVX, levofloxacin; LMX, lomefloxacin; NAL, nalidixic acid; NVB, novobiocin; OXO, oxolinic acid; OFL, ofloxacin; TPZ, trifluoperazine.